Editorial: ustekinumab during pregnancy—reassuring but still not enough. Authors' reply
Authors:
- 5 December 2022
- journal article
- editorial
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 57 (1) , 160
Abstract
LINKED CONTENT: This article is linked to Avni‐Biron et al papers. To view these articles, visit https://doi.org/10.1111/apt.17224 and https://doi.org/10.1111/apt.17260Keywords
This publication has 4 references indexed in Scilit:
- Ustekinumab during pregnancy in patients with inflammatory bowel disease: a prospective multicentre cohort studyAlimentary Pharmacology & Therapeutics, 2022
- Drug Safety and Risk of Adverse Outcomes for Pregnant Patients With Inflammatory Bowel DiseaseGastroenterology, 2017
- The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in PregnancyGastroenterology, 2016
- Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safetyGut, 2015